gdc
PSSGuide_2021
Bladder Cancer

Drugs for Bladder Cancer (Urothelial Carcinoma)

Find financial assistance programs available for bladder cancer drugs.

Balversa (erdafitinib)

Drug company: Janssen
833-375-3232

Balversa is a kinase inhibitor used for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) that has susceptible FGFR3 or FGFR2 genetic alteration (as determined by an FDA-approved test) and has progressed during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Janssen offers 2 financial assistance programs for patients who have been prescribed Balversa:

Janssen CarePath Savings Program

With this program, eligible, privately insured patients will pay just $5 per month for Balversa, with an annual benefit up to $25,000. The savings may apply toward copay, coinsurance, or deductible, depending on the patient’s health insurance plan.

Johnson & Johnson Patient Assistance Foundation

This program provides Balversa free of charge to patients who meet certain financial criteria and who are uninsured, underinsured, or enrolled in Medicare Part D.

Bavencio (avelumab)

Drug company: EMD Serono
844-826-8371

Bavencio is a PD-L1 inhibitor used for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) whose disease progressed during or after platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Bavencio is also used as maintenance treatment of patients with locally advanced or metastatic bladder cancer that has not progressed with first-line platinum-containing chemotherapy.

EMD Serono offers 2 financial assistance programs for patients using Bavencio:

CoverOne Co-Pay Assistance Program

Through this program, patients with private insurance will be responsible for a $0 copay for Bavencio at participating medical facilities and pharmacies, and may be eligible for copay assistance up to a maximum of $30,000 annually.

CoverOne Patient Assistance Program

This program provides Bavencio at no charge for patients who meet certain income, insurance, and residency eligibility criteria.

Jelmyto (mitomycin)

Drug company: UroGen Pharma
855-535-6986

Jelmyto is a first-in-class alkylating drug, a pyelocalyceal solution used for the treatment of adults with low-grade upper tract urothelial cancer.

UroGen Support offers 2 financial assistance programs for patients who have been prescribed Jelmyto:

UroGen Support Copay Program

Eligible patients who have commercial or private health insurance will pay as little as $50 per dose of Jelmyto, with a maximum benefit of $4,000 per dose, and a maximum total benefit of up to $13,000 per year. To qualify for this program, patients must be enrolled in the UroGen Support Program.

UroGen Support Patient Assistance Program

for an FDA-approved indication and have an adjusted gross income of up to 400% of the federal poverty level, may receive Jelmyto for free.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) who are not eligible for cisplatin-containing chemotherapy; and for patients whose disease has progressed during or after platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, regardless of PD-L1 status. Keytruda is also used for the treatment of patients with Bacillus Calmette-Gu rin unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, who are ineligible for or have elected not to undergo cystectomy.

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $64,000 or less for individuals, $87,100 or less for a couple, or $132,000 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

Opdivo (nivolumab)

Drug company: Bristol Myers Squibb
800-861-0048

Opdivo is a PD-1 inhibitor used for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) whose disease progressed during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Opdivo is also indicated for the adjuvant treatment of patients with bladder cancer who are at high risk of recurrence after undergoing radical resection (surgical removal) of the tumor.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Opdivo:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductibles, copay, or coinsurance costs for eligible patients with private insurance who have been prescribed Opdivo. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually per medication.

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Opdivo may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.

Padcev (enfortumab vedotin-ejfv) Injection

Drug company: Astellas/Seagen
888-472-3238

Padcev is a Nectin-4-directed antibody and microtubule inhibitor conjugate used for the treatment of adults with locally advanced or metastatic bladder cancer (urothelial carcinoma) who have received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant or adjuvant, locally advanced or metastatic setting.

Astellas and Seagen offer 2 financial assistance programs for patients using Padcev:

Padcev Copay Assistance Program

Eligible patients who have private insurance pay as little as $5 per dose of Padcev, with a maximum program benefit of $25,000 annually.

Padcev Patient Assistance Program

Eligible patients who are uninsured or underinsured may receive their prescription of Padcev at no cost through this program.

Tecentriq (atezolizumab)

Drug company: Genentech
866-422-2377

Tecentriq is a PD-L1 inhibitor used for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1, as determined by an FDA-approved test; and for patients who are not eligible for platinum-containing therapy, regardless of PD-L1 status.

Genentech Oncology offers 2 financial assistance programs for patients using Tecentriq:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Tecentriq, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Tecentriq free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Trodelvy (sacituzumab govitecanhziy) Injection

Drug company: Gilead
844-876-3358

Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate used for the treatment of adults with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor.

Gilead, through Trodelvy Access Support, offers 2 financial assistance programs for patients using Trodelvy:

Trodelvy Savings Program

Eligible patients who have commercial or private insurance may pay $0 out-of-pocket for Trodelvy, with a maximum benefit of $25,000 per year.

Gilead Patient Assistance Program

Eligible patients who are uninsured or underinsured may receive Trodelvy at no cost.

Table. Drugs Prescribed for Bladder Cancer (Urothelial Carcinoma)

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Bavencio (avelumab)
  • Drug company
  • EMD Serono
  • Indications
  • Treatment of locally advanced or metastatic bladder cancer that progressed during or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy

    Maintenance treatment of locally advanced or metastatic bladder cancer that has not progressed with first-line platinumcontaining chemotherapy
  • Patient support services
  • CoverOne Co-Pay Assistance Program
    844-826-8371

    CoverOne Patient Assistance Program
    844-826-8371


    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indications
  • Treatment of patients with locally advanced or metastatic bladder cancer who are not eligible for platinum-containing therapy and whose tumors express PD- L1, as determined by an FDAapproved test

    Treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy

    Treatment of patients with Bacillus Calmette-Gu rin unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, who are ineligible for or have elected not to undergo cystectomy
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    800-727-5400

    Drug name (generic name)
  • Opdivo (nivolumab)
  • Drug company
  • Bristol Myers Squibb
  • Indications
  • Treatment of locally advanced or metastatic bladder cancer (urothelial carcinoma) that progressed during or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy

    Adjuvant treatment of patients with bladder cancer who are at high risk of recurrence after undergoing radical resection (surgical removal) of the tumor
  • Patient support services
  • BMS Oncology Co-Pay Assistance Program
    800-861-0048

    Bristol Myers Squibb Patient Assistance Foundation
    800-736-0003

    Drug name (generic name)
  • Padcev (enfortumab vedotin-ejfv) Injection
  • Drug company
  • Astellas/Seagen
  • Indication
  • Treatment of locally advanced or metastatic bladder (urothelial) cancer after treatment with a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant or adjuvant, locally advanced or metastatic setting
  • Patient support services
  • Padcev Copay Assistance Program
    888-472-3238

    Padcev Patient Assistance Program
    888-472-3238

    Drug name (generic name)
  • Tecentriq (atezolizumab)
  • Drug company
  • Genentech
  • Indication
  • Treatment of locally advanced or metastatic bladder cancer in patients who are not eligible for cisplatin-containing therapy, and whose tumors express PD-L1, as determined by an FDA-approved tes

    Treatment of patients who are not eligible for any platinum-containing chemotherapy, regardless of PD-L1 status
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331

    Drug name (generic name)
  • Trodelvy (sacituzumab govitecan-hziy) Injection
  • Drug company
  • Gilead
  • Indication
  • Treatment of adults with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor
  • Patient support services
  • Trodelvy Savings Program
    844-876-3358

    Gilead Patient Assistance Program
    844-876-3358

Share this:

Last modified: April 1, 2022

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest